Peregrine Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.89M | Buy |
189,520
+20,053
| +12% | +$729K | 0.21% | 138 |
|
|
2025
Q1 | $6.14M | Buy |
169,467
+5,579
| +3% | +$202K | 0.2% | 148 |
|
|
2024
Q4 | $6.89M | Buy |
163,888
+29,684
| +22% | +$1.25M | 0.2% | 140 |
|
|
2024
Q3 | $7.46M | Sell |
134,204
-14,609
| -10% | -$812K | 0.23% | 117 |
|
|
2024
Q2 | $6.12M | Buy |
148,813
+29,474
| +25% | +$1.21M | 0.18% | 199 |
|
|
2024
Q1 | $5.57M | Buy |
119,339
+39
| +0% | +$1.82K | 0.16% | 220 |
|
|
2023
Q4 | $5.7M | Sell |
119,300
-20,570
| -15% | -$984K | 0.17% | 215 |
|
|
2023
Q3 | $4.99M | Sell |
139,870
-8,774
| -6% | -$313K | 0.15% | 232 |
|
|
2023
Q2 | $6.86M | Sell |
148,644
-43
| -0% | -$1.98K | 0.19% | 223 |
|
|
2023
Q1 | $5.96M | Buy |
148,687
+4,381
| +3% | +$176K | 0.17% | 232 |
|
|
2022
Q4 | $6.69M | Buy |
144,306
+25,377
| +21% | +$1.18M | 0.21% | 218 |
|
|
2022
Q3 | $4.93M | Sell |
118,929
-6,577
| -5% | -$272K | 0.16% | 232 |
|
|
2022
Q2 | $7.49M | Sell |
125,506
-98
| -0.1% | -$5.85K | 0.23% | 198 |
|
|
2022
Q1 | $9.12M | Buy |
+125,604
| New | +$9.12M | 0.22% | 193 |
|